LONDON, Aug 24: British pharmaceutical group GlaxoSmithKline Plc said vercirnon, a drug it was developing to treat Crohn’s disease and licensed from ChemoCentryx, had failed in a late-stage clinical trial. The medicine, which GSK licensed from the California-based company in 2010, did not improve the incidence of adverse events in patients when measured against a placebo, GSK said yesterday, and there was a trend for overall adverse events to increase as dosage levels increased. (agencies)
&&&
Trending Now
E-Paper
Follow our WhatsApp channel